Prelude Therapeutics Incorporated

NasdaqGS PRLD

Prelude Therapeutics Incorporated EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Prelude Therapeutics Incorporated EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: PRLD

Prelude Therapeutics Incorporated

CEO	Dr. Krishna Vaddi D.V.M., Ph.D.
IPO Date	Sept. 25, 2020
Location	United States
Headquarters	200 Powder Mill Road
Employees	128
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Key trends

Past 5 years